Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

OncoSolid™ Bladder Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Bladder Cancer Organoid (BCO) Models

Cancer organoid is a prevailing in vitro model to study the mechanism of tumorigenesis and serves as a clinically related, easy-to-use tool to test the sensitivity of drugs and immunotherapeutics for cancer treatment. Creative Biolabs has developed a cancer organoid platform, including various cancers, to evaluate CAR‐T cells mediated killing against solid tumors. The patient-derived bladder cancer organoids resemble the heterogeneity and biological characteristics of tumor tissue of origin and can be used to predict CAR-T therapeutic responses in vivo.

Fig.1 Establishing well-characterized bladder cancer organoids for potent therapy development. (Lee, et al., 2018)

Bladder Cancer Organoid Subtypes

Multiple subtypes of bladder cancer organoids consist of a high throughput platform for CAR-T efficacy tests.

Types of bladder cancer and derived organoids

Culture Medium

• Classic medium complement with growth factor, R‐spondin 1 and noggin, can support patient-derived bladder cancer cultivation.
• Other formulas with different molecules and growth factors can be explored for customized needs.

Tumor Marker Identification in Organoids

All bladder cancer-related protein antigens are tested to determine the antigen profile of established organoids using specific antibodies.

Our Bladder Cancer Organoids-based CAR-T Efficacy Test Service

Bladder cancer organoids and CAR-T cells cooperate in the co-culture system to test the response of BCOs to immunotherapies in vitro. Specific killing of CAR-T is assessed using cytotoxic assays and ELISA test of cytokine secretion.

Fig.2 Workflow of the co-culture system for CAR-T efficacy tests. (Creative Biolabs)

Bladder Cancer-related CAR-T Products and Services at Creative Biolabs

Creative Biolabs possess a wide range of CAR-T products and kits for bladder cancer study, including CAR vectors, viral particle packaging kits, CAR cells, and so on. Our products have been validated with high performance by global clients.

Case Study

Creative Biolabs has extensive experience in organoids and CAR-T research. If you are interested in our products or services, please do not hesitate to contact us.

References

1. Yu, L.; et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clinical & translational immunology. 2021, 10(2): e1248.
2. Lee, S. H.; et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Cell. 2018, 173(2): 515–528.e17.